A-DIFLUOROMETHYLORNITHINE IN PATIENTS WITH ADVANCED BREAST CANCER

A-二氟甲基鸟氨酸治疗晚期乳腺癌患者

• 批准号: 6286808
• 负责人: ANDREA MANNI
• 金额: $ 3.26万
• 依托单位: PENNSYLVANIA STATE UNIV HERSHEY MED CTR
• 依托单位国家: 美国
• 财政年份: 1995
• 资助国家: 美国
• 起止时间: 1995-08-15 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6286808
• 关键词: acetylcholine; arm; breast neoplasms; clinical research; difluoromethylornithine; human subject; human therapy evaluation; muscle contraction; muscle tone; neoplasm /cancer chemotherapy; neuromuscular function; neuroregulation; pyridostigmine; ultrasound blood flow measurement; vascular smooth muscle nervous control

Polyamine metabolism appears to be important in the proliferation of cancewr cells and the carcinogenic process. Alpha-difluoromethylornithine (DFMO) interferes with polyamine biosynthesis. Preclinical and clinical data indicate DFMO can inhibit ornithine decarboxylase (ODC), the first rate-limiting enzyme in the activation of the polyamine pathway. Increased ODC activity has been shown to be an important prognostic factor for survival in breast cancer specimens taken directly from patients. This study proposes to evaluate DFMO in patients with hormone refractory advanced breast cancer.

多胺代谢似乎在癌细胞的增殖和致癌过程中起着重要作用。α-二氟甲基鸟氨酸(DFMO)干扰多胺的生物合成。临床前和临床数据表明，DFMO可以抑制鸟氨酸脱羧酶(ODC)，这是多胺途径激活的第一个限速酶。在直接取自患者的乳腺癌标本中，ODC活性的增加已被证明是一个重要的预后因素。这项研究建议评估DFMO在激素难治性晚期乳腺癌患者中的作用。